Could a quicker dose Ramp-Up make CLL treatment easier?
NCT ID NCT04843904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely increase their dose of the drug venetoclax faster than the usual 5-week schedule. About 40 participants with newly diagnosed or returning disease will be grouped by their risk of tumor lysis syndrome, a potential side effect. The goal is to find the safest fastest ramp-up and see how well the treatment controls the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States